

Appl. No. : 10/027,603
Filed : December 19, 2001

CONT. CHAND.
A

the latter claiming priority under 35 U.S.C. § 119(e) to provisional application number 60/145,698 filed on July 26, 1999 (now abandoned), and under 35 U.S.C. §120, as a continuation-in-part, to PCT/US99/12252 filed on June 2, 1999, which in turn claim priority under 35 U.S.C. § 119(e) to provisional application number 60/096,146 filed on August 11, 1998 (now abandoned). The present application further claims priority under 35 U.S.C. § 120, as a continuation-in-part, to application serial number 09/709,238 filed on November 8, 2000, which is a continuation of application serial number 09/380,137 filed on August 25, 1999, which is a national phase application of PCT application number PCT/US99/12252, and which claims priority under 35 U.S.C. §119(e) to provisional application number 60/096,146 filed on August 11, 1998 (now abandoned).

Please replace the paragraph beginning on page 7, line 26 with the following replacement paragraph:

2
X

The invention further concerns anti-EG-VEGF antibodies, in particular anti-EG-VEGF monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6, and antibodies that bind essentially the same epitope(s) as any of these antibodies. Fragments of such antibodies, as well as chimeric, humanized, or human antibodies sharing an epitope with any of monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6 are specifically included herein, as are antibody variants comprising amino acid alterations (substitutions, insertions and/or deletions) within the sequence, including the variable region, of such antibodies, as long as the antibodies retain the qualitative antigen-binding properties of any of monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6.

Please replace the paragraph beginning on page 12, line 22 with the following replacement paragraph:

3
A

Figure 21 shows the effect of increasing concentrations of monoclonal antibodies 1C6.1H6.1D7, 2A3.1C5.1F3, 2A8.1H4.1E7 and 4H9.1A7.1H6, as well as combinations of these antibodies, on the proliferative effect of EG-VEGF.

Please replace the paragraph beginning on page 114, line 5 with the following replacement paragraph: